SCHEMBL2828708

SCHEMBL2828708

C=CC(=O)Nc1cccc(Nc2nn3c(-c4ccc(OC)cc4)nnc3c3ccccc23)c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.51
NPSR1 Q6W5P4 2/20 0.51
NPC1 O15118 1/20 0.51
LMNA P02545 1/20 0.51
RAB9A P51151 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
BTK Q06187 4/20 0.50
TP53 P04637 1/20 0.48
EGFR P00533 9/20 0.47
JAK3 P52333 1/20 0.47
ITK Q08881 2/20 0.47
POLB P06746 2/20 0.47
KDM4E B2RXH2 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
SRC P12931 1/20 0.47
FLT3 P36888 1/20 0.46
BLK P51451 1/20 0.46
KCNH2 Q12809 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2828301 0.89 POLB (0.60) MAPTNPSR1NPC1LMNARAB9A
SCHEMBL2828630 0.88 MAPT (0.57) MAPTNPSR1NPC1LMNARAB9A
Cyclopropane SCHEMBL2825655 0.88 MAPT (0.53) MAPTNPSR1NPC1LMNARAB9A
SCHEMBL2827889 0.88 MAPT (0.61) MAPTNPSR1NPC1LMNARAB9A
SCHEMBL2856247 0.87 MAPT (0.52) MAPTNPSR1NPC1LMNARAB9A
SCHEMBL2829203 0.87 MAPT (0.52) MAPTNPSR1NPC1LMNARAB9A
SCHEMBL2828885 0.86 MAPT (0.51) MAPTNPSR1NPC1LMNARAB9A
SCHEMBL2851345 0.86 MAPT (0.55) MAPTNPSR1NPC1LMNARAB9A
SCHEMBL2826309 0.85 MAPT (0.50) MAPTNPSR1NPC1LMNARAB9A
SCHEMBL2825201 0.85 MAPT (0.50) MAPTNPSR1NPC1LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851472-B2 Triazolophthalazines NYCOMED GMBH (DE) 2010-12-14 US disclosed
US-20100286140-A1 TRIAZOLOPHTHALAZINES NYCOMED GMBH (DE) 2010-11-11 US disclosed
EP-1791543-B1 TRIAZOLOPHTHALAZINES NYCOMED GMBH (DE) 2010-06-16 EP disclosed
US-20090005372-A1 Triazolophthalazines ALTANA PHARMA AG (DE) 2009-01-01 US disclosed
EP-1791543-A2 TRIAZOLOPHTHALAZINES Altana Pharma AG (DE) 2007-06-06 EP disclosed
WO-2006024640-A2 TRIAZOLOPHTHALAZINES ALTANA PHARMA AG (DE) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286140-A1 TRIAZOLOPHTHALAZINES PDE2A, PDE12, PDE3A MAPT 3816/4885NPSR1 637/4885NPC1 3556/4885
US-20090005372-A1 Triazolophthalazines PDE2A, PDE12, PDE3A MAPT 3816/4885NPSR1 637/4885NPC1 3556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.